JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Setting

Support: [email protected]

Track Your Order

JAK

A4141 Baricitinib (LY3009104, INCB028050)
2 Citation

Summary: JAK1/JAK2 inhibitor,selective orally bioavailable

insoluble in EtOH; insoluble in H2O; ≥18.57 mg/mL
A4140 WP1066

Target: STAT|JAK

Summary: JAK2/STAT3 inhibitor,cell-permeable

insoluble in H2O; ≥17.8 mg/mL
A4138 Tofacitinib (CP-690550,Tasocitinib)
1 Citation

Target: JAK

Summary: Janus kinase inhibitor

insoluble in EtOH; insoluble in H2O; ≥15.6 mg/mL
A4137 AZD1480

Target: JAK

Summary: JAK2 inhibitor,ATP-competitive and novel

insoluble in H2O; ≥93.8 mg/mL
A4136 TG101348 (SAR302503)
2 Citation

Target: FLT3|JAK|c-RET

Summary: JAK-2 inhibitor,potent and selective

≥26.23 mg/mL
A4135 Tofacitinib (CP-690550) Citrate
2 Citation

Target: JAK

Summary: Potent JAK inhibitor

≥25.22 mg/mL
A3937 XL019

Target: JAK

Summary: JAK2 inhibitor,potent and selective

insoluble in EtOH; insoluble in H2O; ≥11.125 mg/mL
A3936 WHI-P97

Summary: Janus kinase (JAK)-3 inhibitor

Soluble in DMSO
A3794 SB1317

Summary: CDK,JAK and FLT inhibitor

insoluble in H2O; ≥44.87 mg/mL
A3781 Ruxolitinib phosphate

Summary: JAK1/JAK2 inhibitor

≥20.2 mg/mL